Quantification of PFS effect for oncology drug approvals
View Presentation *Cong Chen, Merck & Co., Inc. Linda Z Sun, Merck & Co., Inc. Keywords: Accelerated approval, Bayesian analysis, Surrogate endpoint How to determine whether the outcome from a registration trial with PFS as the primary endpoint is reasonably likely to predict an OS benefit, a requirement for approvals? Since there is no guidance, regulatory agencies tend to look for a compelling PFS effect coupled with an OS effect in the right direction without specification of the effect sizes and significance levels. To address this issue, we propose a synthesized approach to explicitly address the implicit OS objective. The proposed approach is applied to real examples in the metastatic breast cancer setting and hypothetical examples in other settings. The design based on our approach will have a greater sample size than a conventional PFS trial but smaller sample size than a onventional OS trial. It directly addresses the elusive OS question that a conventional PFS trial cannot, no matter how good a surrogate endpoint PFS is.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC